Subscribe Sign In

Why register?

Home
News
Events
- Find an event
- Live event coverage
Deep Dive
Sales and marketing
Digital
Market Access
Oncology
Patients
R&D
Spotlight On
- Frontiers Health 2021
- The Future of Generics
Advertise

Search

Search

Close

Trending

Survival data firms up Trodelvy prospects in new breast cancer use

UK first to approve Moderna’s Omicron booster jab

Evidence-backed VR therapy helps patients overcome phobias

Strike three for Novartis’ canakinumab as lung cancer therapy

Enhertu role in breast cancer confirmed, as Daiichi wins Seagen dispute

Acute Lymphocytic Leukaemia

Moving from autologous to allogeneic ACT paradigms

Deep Dive/ Oncology/ Views & Analysis/ Views and analysis

Moving from autologous to allogeneic ACT paradigms

mike.hammerton@pharmaphorum.com ACT, Acute Lymphocytic Leukaemia, Adoptive Cellular Transfer, CAR T, Deep Dive: Oncology and ASCO 2019, Gilead, ICON, Novartis 0 Comment

We have come so far in a relatively short time with Adoptive Cellular Transfer (ACT). The two marketed

X

Moving from autologous to allogeneic ACT paradigms

https://pharmaphorum.com/deep-dive/icon-allogeneic-adoptive-cellular-transfer/

Get in-depth news, opinions and features on pharma and healthcare sent straight to your inbox

Featured content

How to improve payer engagement with tailored value communication

How to improve payer engagement with tailored value communication

How will NICE fare in a post-Brexit world?

How will NICE fare in a post-Brexit world?

Events

MAPS 2018 EMEA Annual Meeting

MAPS 2018 EMEA Annual Meeting

Cell & Gene Therapy 2018

Cell & Gene Therapy 2018

Patient Engagement Event - a real world snapshot, beyond the talk

Patient Engagement Event - a real world snapshot, beyond the talk

Most popular

Most Viewed

Novartis reports two liver-related deaths with Zolgensma
Enhertu role in breast cancer confirmed, as Daiichi wins Seagen dispute
UK first to approve Moderna's Omicron booster jab
Strike three for Novartis' canakinumab as lung cancer therapy
Survival data firms up Trodelvy prospects in new breast cancer use

Tweets from @pharmaphorum

Tweets by @pharmaphorum

Advertise
pharmaphorum connect

Contribute
Work for pharmaphorum

About us
Contact us
Privacy policy
Terms & conditions
Cookie Policy

The rights of trade mark owners are acknowledged. pharmaphorum media limited

Website and content copyright © 2009-, pharmaphorum media limited or its licensors; all rights reserved.

© 2022

Powered by WordPress • Themify WordPress Themes

Login

Username or Email Address

Password

Remember Me

Lost your password?

CONTINUE TO SITE >

Close in 10 seconds

Pharmaphorum.com